Synthetic DMARDs may be used rheumatoid arthritis mortality and morbidity monotherapy or in combination, and can be co-prescribed with low-dose corticosteroids if necessary. Biologic DMARD therapy should be considered for patients who have failed a 6-month trial of at least 3 synthetic DMARDs.
These recommendations provide practical suggestions for the screening and management of TB and other comorbidities, and offer an approach to monitoring of RA patients. Copyright of published material remains in the Authors’ name. This allows authors to use their work for their own non-commercial purposes without seeking permission from the Publisher, subject to properly acknowledging the Journal as the original place of publication. Authors are free to copy, print and distribute their articles, in full or in part, for teaching activities, and to deposit or include their work in their own personal or institutional database or on-line website. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement.
6-month trial of at least 3 synthetic DMARDs. Algorithm for management of rheumatoid arthritis in SA. RA than the previous ACR criteria. ACR 20, ACR 50 or ACR 70 response. MTX for moderate to severe disease.
DMARDs have controlled the disease. SA, there is no reliable test for LTBI. TST and IGRA may be the best strategy. CXR, should be given anti-TB chemoprophylaxis. 808 per 100 000 in the general population. Felty’s syndrome, and low socio-economic status. TB, but cases have been reported.